QUOTED. Nov. 22, 2017. Pierre Chauvineau.
Check out what Boston Scientific's Pierre Chauvineau had to say about the US possibly being the firm's first go-to market for new products.
"If you were a company what would you do? If you have a market as large as the US, with one language [and] one regulation, and if you can get regulatory approval faster in the US, or at least at the same time as Europe, you'd want to invest in the US, not in Europe. We hope it isn't going to cause too much disruption in the technological innovation. That said, we do agree that we need quality products with quality outcomes – but there needs to be a fine balance." – Pierre Chauvineau, VP executive advisor, Boston Scientific
Click here for a free trial of Medtech Insight